NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.84 -0.52 (-0.62%) GOLD FUTURES
2,328.90 -13.20 (-0.56%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,615.04 -1,659.78 (-3.12%)
MRNA Jun 2024 115.000 call
| Previous close | 6.15 |
| Open | 7.55 |
| Bid | 6.65 |
| Ask | 6.80 |
| Strike | 115.00 |
| Expiry date | 2024-06-21 |
| Day's range | 5.85 - 7.55 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.96k |
Investor's Business DailyAnalysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
ReutersPfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.
CityAMThis may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting today
The English part of a global dispute billion dollar legal case involving big pharma giants Modern, Pfizer and BioNTech over Covid patents, kicks off today.
